

Personal information

First name, Surname:	Harald, Husebye		
Date of birth:	14.01.1966	Sex:	M
Nationality:	Norwegian		

Education

Year	Faculty/department - University/institution - Country
1997	PhD-Department of Food Science, Faculty of Natural Sciences, NMBU - Norway
1992	Master-Department of Biology, MTFS, Faculty of Natural Science, NTNU-Norway

Positions - current and previous

Year	Job title – Employer - Country
1998	Post doc-National Diagnostic Centre, National University of Ireland, Galway- Ireland
1999-2002	Post doc-Department of Biology, Faculty of Natural Science, NTNU - Norway
2003-2010	Researcher- Faculty of Medicine and Health Science (IKOM), NTNU - Norway
2011	Guest researcher, Institute for Systems Biology, Seattle WA - USA
2011-2025	Senior researcher- IKOM, NTNU-Norway

Project management experience

Year	Project owner - Project - Role - Funder
2011-2013	IKOM, NTNU- Mechanisms of Toll-like receptor 4 (TLR4) signaling and its regulation- principal investigator -Samarbeidsorganet for HEMIT og NTNU
2011	Institute for Systems Biology, Seattle WA, USA - Francisella tularensis-Guest researcher- Defense Threat Reduction Agency contract HDTRA
2015-2016	IKOM, NTNU- The involvement of small GTPases in LPS induced type I interferons -principal investigator- FFU, St. Olavs University Hospital and MH faculty, NTNU.
2018-2022	IKOM, NTNU -Rab11-FIP2 and cell death- Main supervisor of PhD-student-Research Council of Norway (RCN) (T. Espevik).
2018-	IKOM, NTNU- UPEC <i>virulence</i> factors and macrophage cell death. A collaboration with Jan Egil Afset at St. Olavs University Hospital- principal investigator -RCN-CEMIR
2024-	IKOM, NTNU -Intracellular complement- Main supervisor PhD student – RCN (T. Espevik)

Supervision of students

Master's students	Ph.D. students	University/institution - Country

2		Department of Biotechnology and Food Science, NMBU-Norway.
2		Department of Biology, Faculty of Natural Science, NTNU-Norway
8		IKOM, NTNU – Norway
1		Utrecht University - The Netherlands/ IKOM, NTNU – Norway
1		Forskerlinje Masterstudent-IKOM, NTNU-Norway
	4	University of Messina-Italy / IKOM, NTNU-Norway (visiting 18, 10, 8 and 8 months)
	1	IKOM, MH, NTNU -Norway (2018, have not defended)
	1	IKOM, MH, NTNU -Norway (started March 2023)

Other relevant professional experiences

Year	Description - Role
2014, 2016	MH Faculty, NTNU – PhD defence for <u>Mari Løset</u> and <u>Kim A. H. Stiberg</u> -3 rd Oponent
2017	Oslo University Hospital, Norway -2 nd opponent for Anne Marthe Fosdahl
2024	Ørebro University, Sweden, Member of PhD Committee for Matthew Herring
2014-24	MH Faculty, NTNU. Appointed dean for 3 PhD defenses
2008-2025	Reviewing: <i>FEBS Journal</i> (2008, 2010), <i>PLOS ONE</i> (2014), <i>Journal of Cell Science</i> (2015), <i>Nature Communications</i> (2015), <i>Journal of Leukocyte Biology</i> (2016), <i>Journal of Inflammation</i> (2017), <i>Cell Proliferation</i> (2017), <i>PNAS</i> (2018), <i>Science Translational Medicine</i> (2019/revision 2022), <i>Frontiers in Immunology</i> (2020), <i>Scandinavian Journal of Immunology</i> (2021), <i>Traffic J</i> (2022), <i>Life Science</i> (2024), <i>EMBO Reports</i> (2024/revision2025)- Reviewer
2025	Commentary in Immunity Cell Biology: TLR4 endocytosis and IFN β -signaling- Author
2008-2012	Collaboration with Dr. L. O'Neill and S. Doyle, Trinity College, Ireland - principal investigator.
2014-2019	Collaboration with Dr. G. Teti, University of Messina, Italy- Supervisor of 4 PhD students
2018-2022	Collaboration with Dr. A-L Gruzman, Bar-Ilan University, Israel, peptidomimetic compounds – principal investigator.

Track record

- Total number of publications during career.
 - 25 peer reviewed scientific journals publications; 6 as first and 4 as senior author.
 - 5 book chapters, 2 as first author.
 - 1 manuscript in external review: Gravastrand et al, Rab11FIP2 controls NLRP3 inflammasome activation through Rab11b, in review EMBO Journal May 2025.
 - 1 manuscript in preparation: Gravastrand et al. The Rab11-family interacting protein 2 control uropathogenic E. coli stimulated cell death through NLRP3, HH senior author.
- Granted patent: United Kingdom Patent Application No. 2008888.6, NTNU, Therapeutic Binding Agents.
- Fellowships, awards and prizes: Medical Technology Research Award (2011 and 2007), Faculty of Medicine and Health Sciences, NTNU; FUGE international travel grant (2011), Faculty of Medicine and Health Sciences, NTNU.